ImmuPharma（IMM）株式概要バイオ医薬品会社であるイミュファーマ社は、英国でペプチドベースの治療薬を発見・開発している。 詳細IMM ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析収益が 100 万ドル未満 ( £0 )UK市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( £29M )最新の財務報告は6か月以上前のものである +1 さらなるリスクすべてのリスクチェックを見るIMM Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUK£Current PriceUK£0.047該当なし内在価値ディスカウントEst. Revenue$PastFuture-8m248k2016201920222025202620282031Revenue UK£0.02Earnings UK£0.002AdvancedSet Fair ValueView all narrativesImmuPharma plc 競合他社Sareum HoldingsSymbol: AIM:SARMarket cap: UK£29.1mPoolbeg PharmaSymbol: AIM:POLBMarket cap: UK£34.9mECO Animal Health GroupSymbol: AIM:EAHMarket cap: UK£65.7mNuformixSymbol: LSE:NFXMarket cap: UK£4.4m価格と性能株価の高値、安値、推移の概要ImmuPharma過去の株価現在の株価UK£0.04752週高値UK£0.1952週安値UK£0.014ベータ2.981ヶ月の変化2.07%3ヶ月変化-44.76%1年変化73.25%3年間の変化51.21%5年間の変化-47.48%IPOからの変化-91.14%最新ニュースお知らせ • May 06ImmuPharma PLC Initiates IND-Enabling Program for Kapiglucagon to Treat DiabetesImmuPharma PLC initiated IND-enabling activities for its Kapiglucagon diabetes program, following the execution of a 'Work Order' with specialist pharmaceutical consultancy tranScrip Limited. Under the agreement, tranScrip will support the development of the regulatory strategy and the preparation and execution of a pre-IND meeting with the FDA, including the preparation of an integrated briefing package and IND planning activities. The program is expected to progress through a streamlined development pathway, with ImmuPharma evaluating a 505(b)(2) regulatory approach in the United States, leveraging existing data on native glucagon, subject to FDA confirmation. Kapiglucagon is a proprietary glucagon prodrug being developed for the treatment of Type 1 diabetes (T1D), to overcome the inherent physicochemical limitations of native glucagon. The program is designed to improve solubility and formulation stability, with potential application in dual-hormone artificial pancreas systems and other glucagon-based therapeutic settings, which are expected to support the development of next-generation alternatives to current insulin-only pump devices. The global Insulin Pump market is forecast to reach $13.6 billion sales by 2035. ImmuPharma has previously stated that it has an accelerated development plan for Kapiglucagon, through a 505(b)(2) regulatory pathway and that the program is being supported by the recently approved funding initiative, which is intended to advance the asset over the next two years. Kapiglucagon has established a strong scientific rationale and a growing body of supporting manufacturing and preclinical data, which the Company believes provides a solid foundation for further development. A key milestone in the IND-enabling process will be a pre-IND meeting with the FDA to align on the regulatory pathway and the scope of the required Chemistry, Manufacturing and Controls (CMC), preclinical and clinical program. Following this meeting, ImmuPharma intends to progress towards IND submission and, subject to regulatory alignment, first-in-human studies to support the next stage of value creation for Kapiglucagon. Kapiglucagon has been developed to address the key pharmaceutical limitations associated with native glucagon. It is a water-soluble glucagon prodrug designed to maintain high stability in aqueous solution while regenerating native glucagon in vivo following subcutaneous administration. Unlike native glucagon, which rapidly aggregates and forms fibrils in solution, Kapiglucagon demonstrates excellent solubility and formulation stability, enabling the development of clean, saline-based formulations that do not clog pump-based delivery systems. This improved physicochemical profile makes Kapiglucagon particularly well suited for continuous or intermittent delivery in advanced diabetes technologies, including next-generation artificial pancreas systems. By combining the therapeutic activity of native glucagon with a formulation that overcomes its inherent instability, Kapiglucagon has the potential to provide more reliable and practical dual-hormone automated glucose control solutions for patients with Type 1 Diabetes and avoid the long-term health complications of inadequate blood glucose control. ImmuPharma's vision is to position Kapiglucagon as a key enabling solution for next-generation artificial pancreas technologies. By overcoming the long-standing instability of native glucagon in aqueous formulations, Kapiglucagon offers the potential to deliver a stable, pump-compatible glucagon source, allowing dual-hormone closed-loop systems to operate safely and effectively. A 505(b)(2) is a U.S. FDA drug approval pathway that sits between a full NDA and a generic. The 505(b)(2) approval route allows a company to obtain approval for a modified version of an existing drug by relying partly on data which the FDA already has for the reference product, in this case a glucagon brand. The timeframe, cost and clinical study requirements for completing such a program may be considerably reduced compared to a normal NDA (new drug application) that follows a full 505(b)(1) NDA development pathway. A (PTE) Patent Term Extension of 5 years may also be applied to the existing patent life of Kapiglucagon which could result in a patent expiry extension to 2043. Kapiglucagon has established a strong scientific rationale and a growing body of supporting CMC and preclinical data, which the Company believes provides a solid foundation for further development. The first step is expected to be a Pre-IND meeting with the FDA to align on the proposed regulatory pathway and the scope of the required CMC, preclinical and clinical program. Following this interaction, the Company intends to advance the remaining development activities, including IND-enabling work, with the objective of entering a focused clinical study designed to generate safety, pharmacokinetic and pharmacodynamic data to support the next stage of value creation for Kapiglucagon.New Risk • Apr 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (UK£29.0m market cap, or US$38.9m).お知らせ • Mar 28ImmuPharma PLC Provides Update on P140 Program Patent Progress and Supporting DataImmuPharma PLC had received a first Combined Search and Examination Report in relation to its United Kingdom patent application for P140, filed in September 2025. The supportive response is as expected by management at this stage of the patent examination process and represents an important positive milestone in the ongoing progress of the application. ImmuPharma intends, in due course, to build on this filing through a Patent Cooperation Treaty ("PCT") application, with a view to seeking protection in key commercial territories. In parallel, ImmuPharma has completed a new study, intended to provide further supporting data for the patent application. The study was designed to stress test the associated diagnostic test and strengthen the statistical significance of the supporting dataset. The results were positive and supportive of the patent application. The scientific team is preparing a scientific manuscript describing the P140 technology platform and its mechanism of action, including recent supporting data. The Company intends to submit the manuscript to a peer-reviewed journal in due course. Following publication, the findings will be shared more broadly with the scientific community. P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value-enhancing licensing deal in 2026. ImmuPharma will provide further updates on the P140 program as appropriate.お知らせ • Mar 23ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £0.468747 million.ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £0.468747 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,812,447 Price\Range: £0.06お知らせ • Mar 17ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £6 million.ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.06New Risk • Feb 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (UK£42.7m market cap, or US$57.6m).最新情報をもっと見るRecent updatesお知らせ • May 06ImmuPharma PLC Initiates IND-Enabling Program for Kapiglucagon to Treat DiabetesImmuPharma PLC initiated IND-enabling activities for its Kapiglucagon diabetes program, following the execution of a 'Work Order' with specialist pharmaceutical consultancy tranScrip Limited. Under the agreement, tranScrip will support the development of the regulatory strategy and the preparation and execution of a pre-IND meeting with the FDA, including the preparation of an integrated briefing package and IND planning activities. The program is expected to progress through a streamlined development pathway, with ImmuPharma evaluating a 505(b)(2) regulatory approach in the United States, leveraging existing data on native glucagon, subject to FDA confirmation. Kapiglucagon is a proprietary glucagon prodrug being developed for the treatment of Type 1 diabetes (T1D), to overcome the inherent physicochemical limitations of native glucagon. The program is designed to improve solubility and formulation stability, with potential application in dual-hormone artificial pancreas systems and other glucagon-based therapeutic settings, which are expected to support the development of next-generation alternatives to current insulin-only pump devices. The global Insulin Pump market is forecast to reach $13.6 billion sales by 2035. ImmuPharma has previously stated that it has an accelerated development plan for Kapiglucagon, through a 505(b)(2) regulatory pathway and that the program is being supported by the recently approved funding initiative, which is intended to advance the asset over the next two years. Kapiglucagon has established a strong scientific rationale and a growing body of supporting manufacturing and preclinical data, which the Company believes provides a solid foundation for further development. A key milestone in the IND-enabling process will be a pre-IND meeting with the FDA to align on the regulatory pathway and the scope of the required Chemistry, Manufacturing and Controls (CMC), preclinical and clinical program. Following this meeting, ImmuPharma intends to progress towards IND submission and, subject to regulatory alignment, first-in-human studies to support the next stage of value creation for Kapiglucagon. Kapiglucagon has been developed to address the key pharmaceutical limitations associated with native glucagon. It is a water-soluble glucagon prodrug designed to maintain high stability in aqueous solution while regenerating native glucagon in vivo following subcutaneous administration. Unlike native glucagon, which rapidly aggregates and forms fibrils in solution, Kapiglucagon demonstrates excellent solubility and formulation stability, enabling the development of clean, saline-based formulations that do not clog pump-based delivery systems. This improved physicochemical profile makes Kapiglucagon particularly well suited for continuous or intermittent delivery in advanced diabetes technologies, including next-generation artificial pancreas systems. By combining the therapeutic activity of native glucagon with a formulation that overcomes its inherent instability, Kapiglucagon has the potential to provide more reliable and practical dual-hormone automated glucose control solutions for patients with Type 1 Diabetes and avoid the long-term health complications of inadequate blood glucose control. ImmuPharma's vision is to position Kapiglucagon as a key enabling solution for next-generation artificial pancreas technologies. By overcoming the long-standing instability of native glucagon in aqueous formulations, Kapiglucagon offers the potential to deliver a stable, pump-compatible glucagon source, allowing dual-hormone closed-loop systems to operate safely and effectively. A 505(b)(2) is a U.S. FDA drug approval pathway that sits between a full NDA and a generic. The 505(b)(2) approval route allows a company to obtain approval for a modified version of an existing drug by relying partly on data which the FDA already has for the reference product, in this case a glucagon brand. The timeframe, cost and clinical study requirements for completing such a program may be considerably reduced compared to a normal NDA (new drug application) that follows a full 505(b)(1) NDA development pathway. A (PTE) Patent Term Extension of 5 years may also be applied to the existing patent life of Kapiglucagon which could result in a patent expiry extension to 2043. Kapiglucagon has established a strong scientific rationale and a growing body of supporting CMC and preclinical data, which the Company believes provides a solid foundation for further development. The first step is expected to be a Pre-IND meeting with the FDA to align on the proposed regulatory pathway and the scope of the required CMC, preclinical and clinical program. Following this interaction, the Company intends to advance the remaining development activities, including IND-enabling work, with the objective of entering a focused clinical study designed to generate safety, pharmacokinetic and pharmacodynamic data to support the next stage of value creation for Kapiglucagon.New Risk • Apr 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (UK£29.0m market cap, or US$38.9m).お知らせ • Mar 28ImmuPharma PLC Provides Update on P140 Program Patent Progress and Supporting DataImmuPharma PLC had received a first Combined Search and Examination Report in relation to its United Kingdom patent application for P140, filed in September 2025. The supportive response is as expected by management at this stage of the patent examination process and represents an important positive milestone in the ongoing progress of the application. ImmuPharma intends, in due course, to build on this filing through a Patent Cooperation Treaty ("PCT") application, with a view to seeking protection in key commercial territories. In parallel, ImmuPharma has completed a new study, intended to provide further supporting data for the patent application. The study was designed to stress test the associated diagnostic test and strengthen the statistical significance of the supporting dataset. The results were positive and supportive of the patent application. The scientific team is preparing a scientific manuscript describing the P140 technology platform and its mechanism of action, including recent supporting data. The Company intends to submit the manuscript to a peer-reviewed journal in due course. Following publication, the findings will be shared more broadly with the scientific community. P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value-enhancing licensing deal in 2026. ImmuPharma will provide further updates on the P140 program as appropriate.お知らせ • Mar 23ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £0.468747 million.ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £0.468747 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,812,447 Price\Range: £0.06お知らせ • Mar 17ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £6 million.ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.06New Risk • Feb 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (UK£42.7m market cap, or US$57.6m).お知らせ • Oct 13ImmuPharma plc Announces Appointment of Ketan Patel as an Independent Non-Executive Director, effective October 13, 2025ImmuPharma plc announced the appointment of Ketan Patel to the Board, as an independent Non-Executive Director. The appointment is with immediate effect October 13, 2025. Ketanis an experienced investment professionaland brings extensive expertise in financial markets with a focus in the UK healthcare and life science sectors. He has been a long-term investor in UK markets, as an analyst and Fund Manager, running institutional, retail and charity mandates. Ketan started his career at JP Morgan, before moving to Insight Investment where he was a global Pharmaceutical and Healthcare analyst and spent over 20 years at EdenTree Investment Management where he was responsible for UK equity and global equity income strategiesdelivering consistent upper quartile performance. Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes, Ketan is a CFA Charterholder. He also holds anMSc Economic History, fromLondon School of Economics, MSc Geography from King's College London and BA (Hons) History and Geography from Queen Mary University, London.Board Change • Sep 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Senior Independent Non-Executive Director Laurence Reilly was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Aug 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£1.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (UK£8.43m market cap, or US$11.3m).お知らせ • May 20ImmuPharma plc, Annual General Meeting, Jun 12, 2025ImmuPharma plc, Annual General Meeting, Jun 12, 2025. Location: the malmaison hotel, 18 21 charterhouse square, barbican, ec1m 6ah, london United KingdomNew Risk • May 19New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£543k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-UK£543k). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (UK£15.0m market cap, or US$20.0m).New Risk • Apr 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (UK£18.5m market cap, or US$24.6m).New Risk • Mar 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (58% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (UK£12.7m market cap, or US$16.5m).お知らせ • Feb 21ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £2.9095 million.ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £2.9095 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,586,667 Price\Range: £0.0375 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: £0.0375 Transaction Features: Subsequent Direct Listingお知らせ • Feb 14ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £2.9095 million.ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £2.9095 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,586,667 Price\Range: £0.0375 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: £0.0375 Transaction Features: Subsequent Direct Listing分析記事 • Jan 25Is ImmuPharma (LON:IMM) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...お知らせ • Jan 09ImmuPharma plc Announces Breakthrough Findings into Autoimmune DiseasesImmuPharma PLC announced innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company's R&D subsidiary ImmuPharma Biotech, has yielded data that provides novel insights into autoimmune disease mechanisms. Importantly for autoimmune therapy P140, especially for lead indication in SLE, these findings pave the way for: Earlier and more accurate diagnostics; Identifying patients most likely to respond to P140 therapy; and Improved monitoring of the patient's response to treatment with P140. Through this research, the company is making a significant step towards personalised medicine in SLE and other autoimmune diseases. The Company is not at this time releasing detailed data as these findings form part of the ongoing expansion of intellectual property portfolio including additional patents for P140.New Risk • Jan 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.6m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£5.23m market cap, or US$6.53m).お知らせ • Dec 04Immupharma plc Announces Appointment of Ashley Clarke as Company SecretaryImmuPharma plc to confirm the appointment of Ashley Clarke ACA, as Company Secretary to the Company. The appointment is with immediate effect. Ashley has been closely involved with the Company's accounts for several years via outsourced accountants, providing her with deep familiarity with ImmuPharma's operations. Now, as Group CFO, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure continued robust fiscal management. (More details on Ashley in 'Notes to Editors').お知らせ • Sep 17Immunovia Presents Data from Model Development Study At 2024 AACR Advances in Pancreatic Cancer Medical ConferenceImmunovia presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer. Immunovia shared results from the model development study of its next-generation test to detect stage 1 and 2 pancreatic cancer. The company disclosed its method for selecting the biomarkers that comprise the test, the construction of the test algorithm, and the test's performance and stability. In the study of 623 patient samples, the test demonstrated superior performance, with sensitivity of 85% and specificity of 98%, as reported in a 1 August 2024 press release. The sensitivity of the Immunovia test exceeded that of CA19-9, a commonly used biomarker for pancreatic cancer, by 20 percentage points. The conference is being hosted by the American Association for Cancer Research (AACR) in Boston, Massachusetts. This special conference brings together leading pancreatic cancer researchers, physicians, and patient advocates to share innovative approaches for diagnosing and treating pancreatic cancer.お知らせ • Jul 29ImmuPharma plc to Report Q2, 2024 Results on Aug 05, 2024ImmuPharma plc announced that they will report Q2, 2024 results at 8:30 AM, Central European Standard Time on Aug 05, 2024お知らせ • Jun 08ImmuPharma plc, Annual General Meeting, Jun 28, 2024ImmuPharma plc, Annual General Meeting, Jun 28, 2024. Location: the offices of evelyn partners, 45 gresham street, ec2v 7bg, london United Kingdomお知らせ • Apr 30Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory DirectorImmunovia announced the appointment of Dr. Lisa Fordas Clinical Laboratory Director. As Clinical Laboratory Director, Dr. Ford will lead lab operations as well as research and development of Immunovia's next-generation test. Her primary responsibilities will be staffing, developing, and overseeing the laboratory team; quality assurance and regulatory compliance; and facilitating collaboration and communication with external partners, especially Proteomedix. Lisa brings over twenty years of experience leading laboratory project teams through research, development, validation (clinical and analytical) and implementation of diagnostic tests. She has extensive experience overseeing clinical and bioanalytical laboratories and associated quality systems, managing clinical assay development, validation projects, quality improvement and laboratory personnel. Lisa holds a Ph.D. from Duke University in Bioorganic Chemistry and a B.S. from University of California in Chemistry, and board certification as a high-complexity clinical laboratory director from the American Board of Bioanalysis.New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.5m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (UK£70k revenue, or US$89k). Market cap is less than US$10m (UK£7.72m market cap, or US$9.84m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (25% increase in shares outstanding).お知らせ • Dec 19Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic LupuzortmImmuPharma PLC announced key updates on its late stage P140 (Lupuzortm) program, in patients with systemic lupus erythematosus ("SLE/Lupus"). The design of the pivotal Phase 3 study includes a dose-range. This design is faster to complete than a Phase 2/3 adaptive study, while at the same time incorporating all the key objectives. The company confidently expect the efficacious dose to be within this dose-range and The company expects no adverse events that could lead to product label warnings seen with all other approved drugs and standard of care, which are all immunosuppressants. The study design allows two interim analyses, so there will be short term updates on clinical activity of the drug. P140 is not an immunosuppressant, so a key objective will be to taper the use of steroids which are currently standard of care. This distinction sets the stage for a new gold standard therapy, conveniently self-administered by the patient, once a month, which is safe and well tolerated unlike standard of care or any other molecule in development which are all immunosuppressedants with significant safety warnings. Further details on the protocol and key elements of the clinical trial design will be communicated, once the details of the trial are available on clinicaltrials.gov (a comprehensive database of privately and publicly funded clinical studies conducted around the world). The international Phase 3 dose-ranging study design and protocol is substantially different from previous clinical trials completed by ImmuPharma. Dosing will still be a subcutaneous injection, once a month, but with significantly higher doses, which have demonstrated safety and tolerability as part of the clinical program. Two planned interim analyses during the course of the study will allow early indications of the effectiveness of P140. Recent further insights into P140's mechanism of action supports its position as the only non-immunosuppressing molecule in clinical development in the industry. A new potential standard of care for SLE sufferers. As the study continues to move forward in 2024, further details on the study's timings, protocol and key elements of theclinical trial design will be communicated at regular intervals. Simbec-Orion, is an experienced, full-service Contract Research Organisation, with offices across UK, Europe, and the United States, specialising in Rare & Orphan conditions. Simbec-Orion has previous direct experience in Lupus trials including conducting ImmuPharma's last Phase 3 study completed in 2018 and more recently conducted ImmuPharma's Pharmacokinetics (" PK") study completed in 2022. The whole P140 program was re-examined in 2021, and the Board decided that it required a completely different approach, not only to commence a new Phase 3 study in Lupus, but also to be clear on the product offering and target product profile. The three pillars of strength and confidence in new program are dose, design and MOA. Dose After three FDA guidance meetings, further human and animal pharmacokinetics studies and reconciliation with efficacy demonstrated in the animal models, it was concluded that the previous dose used in clinical studies was too low. The new Phase 3 study will include dose-ranging up to 15 times higher than the original study dose of 200 micrograms. Design The design of the pivotal Phase3 study includes a dose- range. This design is faster to completed than a Phase 2/3 Adapted study, while at the sametime incorporating all the key objectives.お知らせ • Nov 09Immunovia Successfully Completes Discovery Phase of Next-Generation Test DevelopmentImmunovia announced the successful completion of the discovery phase for the Company's next-generation test. The discovery study, which marks a key milestone in the development of Immunovia's next-generation test to detect early-stage pancreatic cancer, successfully found more than a dozen proteins circulating in the blood that identified pancreatic ductal adenocarcinoma (PDAC) stage I and stage II patients. The study is the most comprehensive pancreatic proteomics study done to date and utilized the Olink platform to explore nearly 3,000 protein biomarkers. The new test is designed to work across all racial and ethnic groups without compromising accuracy, overcoming a key limitation of Immunovia's first-generation test, IMMray PanCan-d. Immunovia and its development partner Proteomedix are in the process of developing high- quality assays to accurately measure the identified biomarkers. The next step will be to complete a study to select which biomarkers to include in the commercial test, optimize the test, and assess its accuracy. Later in 2024, Immunovia will confirm the analytical validity of the test and conduct a large clinical validation study.Board Change • Oct 12No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. 6 highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Cees Kallenberg is the most experienced director on the board, commencing their role in 2013. Senior independent Non-Executive Director Laurence Reilly was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Aug 12ImmuPharma plc Announces Changes to Its Board of DirectorsImmuPharma plc announced the appointment of Dr. Laurence Reilly as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr. Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience. He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry. Through his consulting practice (Acumen Life Science Investment Consulting) .Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr. Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr Reilly previously served as a Clinician - Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor. Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K. The company also extremely welcomed DrSébastien Goudreau to the Board. Dr Goudreau joined ImmuPharma in 2014 as research director and established the research laboratories of Ureka Pharma (now ImmuPharma Biotech, the Company's French subsidiary) in Bordeaux, being promoted in 2021 to Chief Executive Officer of ImmuPharma Biotech. Notably, working directly with Dr Tim Franklin (ImmuPharma COO), Dr Goudreau and his team are credited for the development of, among others, the Company's anti-infective programmes, BioAMBand BioCin. Dr Goudreau has also been a key contributor to the progression of the P140 autoimmune platform including the PK study, successfully concluded in 2022, and supported the new protocol design of the Phase 2/3 adaptive clinical studies for both Lupus and CIDP. Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. At this time, Dr Sanjeev Pandya, has informed the Board that he wishes to step down from his Non-Executive Director position, in order to pursue a number of other external opportunities. All Board changes take place with immediate effect.お知らせ • Jul 13Immunovia to Significantly Restructure to Focus Resources on Its Next-Generation Blood Test for Pancreatic Cancer DetectionImmunovia announced plans to restructure its operations. The company will cease commercialization of its IMMray PanCan-d test in the United States to focus its resources on the further development and clinical testing of the Company's promising next generation pancreatic cancer detection test. The next generation assay currently in development is intended to work equally well across multiple patient risk groups. The new test is expected to provide accurate results in patients who do not produce CA19-9, and to reduce reliance on CA19-9, which have been limitations of IMMray PanCan-d. The next generation test will be performed on a widely used commercial platform, enabling the company to better scale production. Immunovia expects to release further details about the next-generation test later this year, with an anticipated launch date in 2024. Immunovia's strategic decision to focus on its next generation assay will result in significant layoffs in both Sweden and the United States in multiple functions. Importantly, the staffing reductions and the elimination of other operating expenses will lower the company's cash burn rate and extend the Company's cash reserves well into 2024.New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.82m (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£2.5m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£7.82m market cap, or US$9.94m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).お知らせ • Jun 06ImmuPharma plc, Annual General Meeting, Jun 30, 2023ImmuPharma plc, Annual General Meeting, Jun 30, 2023, at 10:00 Coordinated Universal Time. Location: One Bartholomew Close London, EC1A 7BL London United Kingdomお知らせ • May 23ImmuPharma plc, Annual General Meeting, May 26, 2023ImmuPharma plc, Annual General Meeting, May 26, 2023, at 09:00 Central European Standard Time. Location: The Spark, Scheeletorget 1, Medicon Village, Lund. Lund Swedenお知らせ • May 19+ 1 more updateImmuPharma plc Announces Further Positive Progress in Late-Stage Clinical Program in Patients with Chronic Idiopathic Demyelinating PolyneuropathyImmuPharma PLC announced further positive progress in its late-stage clinical program in patients with chronic idiopathic demyelinating polyneuropathy, which is a further debilitating auto-immune condition within the Company's P140 platform. Key highlights: ImmuPharma has received positive support and guidance from the Food and Drug Administration ("FDA"), following the Pre-Investigational New Drug ("PIND") meeting that confirms the route for a Phase 2/3 adaptive clinical study of P140 in CIDP; The FDA feedback recognises that P140 is suitable to be studied in another disease indication in addition to SLE (systemic lupus erythematosus) and this strongly supports the underlying science and mechanism of action of P140 across several auto-immune/inflammatory diseases and is a significant breakthrough for the P140 platform; The Phase 2/3 adaptive clinical trial will be the first pivotal stage study of P140 in patients with CIDP: a rare neurological disease with high medical need; An IND application will now be prepared for submission to the FDA, incorporating all guidance points and pending approval, company remain on track to commence the Phase 2/3 adaptive clinical trial in H2 2023; An application for Orphan Drug status for CIDP will be also submitted in parallel to the full IND application; The CIDP market is expected to reach global sales of USD 2.7 billion by 2029. This feedback from the FDA provides not only positive support and guidance for an IND application and acceptance of the Phase 2/3 clinical trial design for CIDP, but also recognises the potential therapeutic benefit in another auto-immune/inflammatory disease in addition to P140 (Lupuzor™) in SLE, representing a significant breakthrough for the P140 platform. The Phase 2/3 clinical trial will be the first pivotal stage study of P140 in patients with CIDP: a rare neurological disease with high medical need. The study design was developed with company's contract research organisation (CRO) and CIDP opinion leaders from Europe and the USA. The CIDP protocol is founded on much of the preclinical and clinical work carried out to date on P140 (Lupuzor™) in SLE, which itself is scheduled to begin a Phase 2/3 adaptive clinical trial in Lupus patients in H2 2023. Many elements of the FDA guidance for CIDP, particularly the Phase 2/3 protocol design and dosing, can now be anticipated for the upcoming FDA Type-C meeting for P140 (Lupuzor™) in SLE on or around the 7th June 2023.お知らせ • Jan 20Immunovia Announces Realigning Swedish Operations with Strategic Priorities and Its Focus on the US Commercialization of the IMMray™ PanCan-d testImmunovia announced it is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray™ PanCan-d test. In October 2022, Immunovia announced a research collaboration partnership with Proteomedix. The partnership capitalizes on the combined expertise of two leading innovators in proteomics-based diagnostics. Following the early experience of the collaboration Immunovia has been able to better understand the opportunities available to the company and has determined that the in-house need for R&D capability has changed. As a result, Immunovia has initiated a union consultation process with the aim of reducing the number of employees within R&D and Operations in Lund. Immunovia has initiated a consultation process with relevant Swedish unions to create the best possible transition for the affected employees. The Company will provide an update once the consultation process is concluded.お知らせ • Jan 18Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray PanCan-d test in the US marketImmunovia announced that it has appointed Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs effective February 1, 2023. Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics. Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State University. Her lab focused on the contribution of genomics to cancer susceptibility and survival following diagnosis. Lara brings expertise in designing, implementing, analyzing, and leading large-scale international clinical, biomarker, genomic and epidemiologic studies resulting in national and international scientific presentations and over 130 peer-reviewed publications. Her academic research was funded by the National Institutes of Health and Department of Defense. She has extensive experience in leading clinical science teams and collaborating with key opinion leaders. Lara holds a PhD in Genetic and Molecular Epidemiology from Case Western Reserve University, an MS in Genetic Counseling from The Ohio State University as well as degrees in engineering and economics.Price Target Changed • Nov 16Price target decreased to UK£0.029Down from UK£0.036, the current price target is provided by 1 analyst. New target price is 16% above last closing price of UK£0.025. Stock is down 63% over the past year. The company posted a net loss per share of UK£0.033 last year.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Senior Independent Non-Executive Director Sanjeev Pandya was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 12+ 4 more updatesImmuPharma plc, Annual General Meeting, Apr 27, 2023ImmuPharma plc, Annual General Meeting, Apr 27, 2023.Reported Earnings • Sep 30First half 2022 earnings released: UK£0.006 loss per share (vs UK£0.015 loss in 1H 2021)First half 2022 results: UK£0.006 loss per share (improved from UK£0.015 loss in 1H 2021). Net loss: UK£1.66m (loss narrowed 55% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.Reported Earnings • May 26Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: UK£0.032 loss per share. Net loss: UK£8.17m (loss widened 19% from FY 2020). Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) missed analyst estimates by 12%.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Senior independent Non-Executive Director Sanjeev Pandya was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 03First half 2021 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in 1H 2020)First half 2021 results: Net loss: UK£3.66m (loss widened 24% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Board Change • Aug 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Senior independent Non-Executive Director Sanjeev Pandya was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Executive Departure • Aug 05Independent Non-Executive Director Stéphane Robert Méry has left the companyOn the 30th of July, Stéphane Robert Méry's tenure as Independent Non-Executive Director ended after 6.3 years in the role. As of March 2021, Stéphane Robert still personally held only 21.49k shares (UK£1.9k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Aug 05Senior Independent Non-Executive Director Franco Di Muzio has left the companyOn the 30th of July, Franco Di Muzio's tenure as Senior Independent Non-Executive Director ended. As of March 2021, Franco still personally held only 99.41k shares (UK£8.8k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.Executive Departure • Jul 02Co-Founder, President, Chief Scientific Officer & Director D. Henri Zimmer has left the companyOn the 28th of June, D. Henri Zimmer's tenure as Co-Founder, President, Chief Scientific Officer & Director ended after 15.4 years in the role. As of March 2021, Henri Zimmer still personally held 27.34m shares (UK£2.4m worth at the time). Henri Zimmer is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.33 years, which is considered inexperienced in the Simply Wall St Risk Model.分析記事 • Jun 22Shareholders May Be A Bit More Conservative With ImmuPharma plc's (LON:IMM) CEO Compensation For NowThe underwhelming share price performance of ImmuPharma plc ( LON:IMM ) in the past three years would have disappointed...Reported Earnings • May 01Full year 2020 earnings released: UK£0.034 loss per share (vs UK£0.04 loss in FY 2019)Full year 2020 results: Net loss: UK£6.86m (loss widened 12% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.分析記事 • Dec 02How Much Is ImmuPharma's (LON:IMM) CEO Getting Paid?The CEO of ImmuPharma plc ( LON:IMM ) is Dimitri Dimitriou, and this article examines the executive's compensation...Reported Earnings • Oct 03First half earnings releasedOver the last 12 months the company has reported total losses of UK£5.18m, with losses narrowing by 26% from the prior year.株主還元IMMGB PharmaceuticalsGB 市場7D12.6%2.2%0.3%1Y73.2%26.1%18.8%株主還元を見る業界別リターン: IMM過去 1 年間で26.1 % の収益を上げたUK Pharmaceuticals業界を上回りました。リターン対市場: IMM過去 1 年間で18.8 % の収益を上げたUK市場を上回りました。価格変動Is IMM's price volatile compared to industry and market?IMM volatilityIMM Average Weekly Movement12.4%Pharmaceuticals Industry Average Movement6.1%Market Average Movement5.7%10% most volatile stocks in GB Market11.9%10% least volatile stocks in GB Market3.1%安定した株価: IMMの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: IMMの 週次ボラティリティ は過去 1 年間で25%から12%に減少しましたが、依然としてUK株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19996Tim McCarthywww.immupharma.co.ukイミュファーマ社は、英国でペプチドベースの治療薬を創製・開発しているバイオ医薬品企業。同社のペプチドベースの治療薬は、自己免疫や炎症、抗感染症の治療分野で使用されている。同社の主要製品候補はペプチド技術プラットフォームであるP140（Lupuzor）で、全身性エリテマトーデスを対象とした自己免疫疾患を対象とした第III相臨床試験中であり、神経の進行性炎症性疾患である慢性炎症性脱髄性多発神経炎を対象とした第II相臨床試験中のP140、喘息、痛風、歯周炎、IBDを対象としたその他の適応症のP140である。前臨床段階の製品としては、アスペルギルス症などの重篤で生命を脅かす真菌感染症に対するアムホテリシン-B製剤の治療薬としてペプチドベースのBioAMB、抗感染症治療薬としてバンコマイシンベースのBioCinなどがある。また、国立科学研究センターとは1P40プラットフォームの開発に関する共同研究契約を、Avion Pharmaceuticals LLCとはライセンスおよび開発契約を結んでいる。イミュファーマ社は1999年に設立され、英国ロンドンに本社を置いている。もっと見るImmuPharma plc 基礎のまとめImmuPharma の収益と売上を時価総額と比較するとどうか。IMM 基礎統計学時価総額UK£29.29m収益（TTM）-UK£3.93m売上高(TTM)n/a0.0xP/Sレシオ-7.4xPER（株価収益率IMM は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計IMM 損益計算書（TTM）収益UK£0売上原価UK£0売上総利益UK£0その他の費用UK£3.93m収益-UK£3.93m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.0063グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%IMM の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 11:13終値2026/05/21 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ImmuPharma plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関null nullCavendishAlexander PyeCavendishChristian GlennieEdison Investment Research1 その他のアナリストを表示
お知らせ • May 06ImmuPharma PLC Initiates IND-Enabling Program for Kapiglucagon to Treat DiabetesImmuPharma PLC initiated IND-enabling activities for its Kapiglucagon diabetes program, following the execution of a 'Work Order' with specialist pharmaceutical consultancy tranScrip Limited. Under the agreement, tranScrip will support the development of the regulatory strategy and the preparation and execution of a pre-IND meeting with the FDA, including the preparation of an integrated briefing package and IND planning activities. The program is expected to progress through a streamlined development pathway, with ImmuPharma evaluating a 505(b)(2) regulatory approach in the United States, leveraging existing data on native glucagon, subject to FDA confirmation. Kapiglucagon is a proprietary glucagon prodrug being developed for the treatment of Type 1 diabetes (T1D), to overcome the inherent physicochemical limitations of native glucagon. The program is designed to improve solubility and formulation stability, with potential application in dual-hormone artificial pancreas systems and other glucagon-based therapeutic settings, which are expected to support the development of next-generation alternatives to current insulin-only pump devices. The global Insulin Pump market is forecast to reach $13.6 billion sales by 2035. ImmuPharma has previously stated that it has an accelerated development plan for Kapiglucagon, through a 505(b)(2) regulatory pathway and that the program is being supported by the recently approved funding initiative, which is intended to advance the asset over the next two years. Kapiglucagon has established a strong scientific rationale and a growing body of supporting manufacturing and preclinical data, which the Company believes provides a solid foundation for further development. A key milestone in the IND-enabling process will be a pre-IND meeting with the FDA to align on the regulatory pathway and the scope of the required Chemistry, Manufacturing and Controls (CMC), preclinical and clinical program. Following this meeting, ImmuPharma intends to progress towards IND submission and, subject to regulatory alignment, first-in-human studies to support the next stage of value creation for Kapiglucagon. Kapiglucagon has been developed to address the key pharmaceutical limitations associated with native glucagon. It is a water-soluble glucagon prodrug designed to maintain high stability in aqueous solution while regenerating native glucagon in vivo following subcutaneous administration. Unlike native glucagon, which rapidly aggregates and forms fibrils in solution, Kapiglucagon demonstrates excellent solubility and formulation stability, enabling the development of clean, saline-based formulations that do not clog pump-based delivery systems. This improved physicochemical profile makes Kapiglucagon particularly well suited for continuous or intermittent delivery in advanced diabetes technologies, including next-generation artificial pancreas systems. By combining the therapeutic activity of native glucagon with a formulation that overcomes its inherent instability, Kapiglucagon has the potential to provide more reliable and practical dual-hormone automated glucose control solutions for patients with Type 1 Diabetes and avoid the long-term health complications of inadequate blood glucose control. ImmuPharma's vision is to position Kapiglucagon as a key enabling solution for next-generation artificial pancreas technologies. By overcoming the long-standing instability of native glucagon in aqueous formulations, Kapiglucagon offers the potential to deliver a stable, pump-compatible glucagon source, allowing dual-hormone closed-loop systems to operate safely and effectively. A 505(b)(2) is a U.S. FDA drug approval pathway that sits between a full NDA and a generic. The 505(b)(2) approval route allows a company to obtain approval for a modified version of an existing drug by relying partly on data which the FDA already has for the reference product, in this case a glucagon brand. The timeframe, cost and clinical study requirements for completing such a program may be considerably reduced compared to a normal NDA (new drug application) that follows a full 505(b)(1) NDA development pathway. A (PTE) Patent Term Extension of 5 years may also be applied to the existing patent life of Kapiglucagon which could result in a patent expiry extension to 2043. Kapiglucagon has established a strong scientific rationale and a growing body of supporting CMC and preclinical data, which the Company believes provides a solid foundation for further development. The first step is expected to be a Pre-IND meeting with the FDA to align on the proposed regulatory pathway and the scope of the required CMC, preclinical and clinical program. Following this interaction, the Company intends to advance the remaining development activities, including IND-enabling work, with the objective of entering a focused clinical study designed to generate safety, pharmacokinetic and pharmacodynamic data to support the next stage of value creation for Kapiglucagon.
New Risk • Apr 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (UK£29.0m market cap, or US$38.9m).
お知らせ • Mar 28ImmuPharma PLC Provides Update on P140 Program Patent Progress and Supporting DataImmuPharma PLC had received a first Combined Search and Examination Report in relation to its United Kingdom patent application for P140, filed in September 2025. The supportive response is as expected by management at this stage of the patent examination process and represents an important positive milestone in the ongoing progress of the application. ImmuPharma intends, in due course, to build on this filing through a Patent Cooperation Treaty ("PCT") application, with a view to seeking protection in key commercial territories. In parallel, ImmuPharma has completed a new study, intended to provide further supporting data for the patent application. The study was designed to stress test the associated diagnostic test and strengthen the statistical significance of the supporting dataset. The results were positive and supportive of the patent application. The scientific team is preparing a scientific manuscript describing the P140 technology platform and its mechanism of action, including recent supporting data. The Company intends to submit the manuscript to a peer-reviewed journal in due course. Following publication, the findings will be shared more broadly with the scientific community. P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value-enhancing licensing deal in 2026. ImmuPharma will provide further updates on the P140 program as appropriate.
お知らせ • Mar 23ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £0.468747 million.ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £0.468747 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,812,447 Price\Range: £0.06
お知らせ • Mar 17ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £6 million.ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.06
New Risk • Feb 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (UK£42.7m market cap, or US$57.6m).
お知らせ • May 06ImmuPharma PLC Initiates IND-Enabling Program for Kapiglucagon to Treat DiabetesImmuPharma PLC initiated IND-enabling activities for its Kapiglucagon diabetes program, following the execution of a 'Work Order' with specialist pharmaceutical consultancy tranScrip Limited. Under the agreement, tranScrip will support the development of the regulatory strategy and the preparation and execution of a pre-IND meeting with the FDA, including the preparation of an integrated briefing package and IND planning activities. The program is expected to progress through a streamlined development pathway, with ImmuPharma evaluating a 505(b)(2) regulatory approach in the United States, leveraging existing data on native glucagon, subject to FDA confirmation. Kapiglucagon is a proprietary glucagon prodrug being developed for the treatment of Type 1 diabetes (T1D), to overcome the inherent physicochemical limitations of native glucagon. The program is designed to improve solubility and formulation stability, with potential application in dual-hormone artificial pancreas systems and other glucagon-based therapeutic settings, which are expected to support the development of next-generation alternatives to current insulin-only pump devices. The global Insulin Pump market is forecast to reach $13.6 billion sales by 2035. ImmuPharma has previously stated that it has an accelerated development plan for Kapiglucagon, through a 505(b)(2) regulatory pathway and that the program is being supported by the recently approved funding initiative, which is intended to advance the asset over the next two years. Kapiglucagon has established a strong scientific rationale and a growing body of supporting manufacturing and preclinical data, which the Company believes provides a solid foundation for further development. A key milestone in the IND-enabling process will be a pre-IND meeting with the FDA to align on the regulatory pathway and the scope of the required Chemistry, Manufacturing and Controls (CMC), preclinical and clinical program. Following this meeting, ImmuPharma intends to progress towards IND submission and, subject to regulatory alignment, first-in-human studies to support the next stage of value creation for Kapiglucagon. Kapiglucagon has been developed to address the key pharmaceutical limitations associated with native glucagon. It is a water-soluble glucagon prodrug designed to maintain high stability in aqueous solution while regenerating native glucagon in vivo following subcutaneous administration. Unlike native glucagon, which rapidly aggregates and forms fibrils in solution, Kapiglucagon demonstrates excellent solubility and formulation stability, enabling the development of clean, saline-based formulations that do not clog pump-based delivery systems. This improved physicochemical profile makes Kapiglucagon particularly well suited for continuous or intermittent delivery in advanced diabetes technologies, including next-generation artificial pancreas systems. By combining the therapeutic activity of native glucagon with a formulation that overcomes its inherent instability, Kapiglucagon has the potential to provide more reliable and practical dual-hormone automated glucose control solutions for patients with Type 1 Diabetes and avoid the long-term health complications of inadequate blood glucose control. ImmuPharma's vision is to position Kapiglucagon as a key enabling solution for next-generation artificial pancreas technologies. By overcoming the long-standing instability of native glucagon in aqueous formulations, Kapiglucagon offers the potential to deliver a stable, pump-compatible glucagon source, allowing dual-hormone closed-loop systems to operate safely and effectively. A 505(b)(2) is a U.S. FDA drug approval pathway that sits between a full NDA and a generic. The 505(b)(2) approval route allows a company to obtain approval for a modified version of an existing drug by relying partly on data which the FDA already has for the reference product, in this case a glucagon brand. The timeframe, cost and clinical study requirements for completing such a program may be considerably reduced compared to a normal NDA (new drug application) that follows a full 505(b)(1) NDA development pathway. A (PTE) Patent Term Extension of 5 years may also be applied to the existing patent life of Kapiglucagon which could result in a patent expiry extension to 2043. Kapiglucagon has established a strong scientific rationale and a growing body of supporting CMC and preclinical data, which the Company believes provides a solid foundation for further development. The first step is expected to be a Pre-IND meeting with the FDA to align on the proposed regulatory pathway and the scope of the required CMC, preclinical and clinical program. Following this interaction, the Company intends to advance the remaining development activities, including IND-enabling work, with the objective of entering a focused clinical study designed to generate safety, pharmacokinetic and pharmacodynamic data to support the next stage of value creation for Kapiglucagon.
New Risk • Apr 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 25% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (UK£29.0m market cap, or US$38.9m).
お知らせ • Mar 28ImmuPharma PLC Provides Update on P140 Program Patent Progress and Supporting DataImmuPharma PLC had received a first Combined Search and Examination Report in relation to its United Kingdom patent application for P140, filed in September 2025. The supportive response is as expected by management at this stage of the patent examination process and represents an important positive milestone in the ongoing progress of the application. ImmuPharma intends, in due course, to build on this filing through a Patent Cooperation Treaty ("PCT") application, with a view to seeking protection in key commercial territories. In parallel, ImmuPharma has completed a new study, intended to provide further supporting data for the patent application. The study was designed to stress test the associated diagnostic test and strengthen the statistical significance of the supporting dataset. The results were positive and supportive of the patent application. The scientific team is preparing a scientific manuscript describing the P140 technology platform and its mechanism of action, including recent supporting data. The Company intends to submit the manuscript to a peer-reviewed journal in due course. Following publication, the findings will be shared more broadly with the scientific community. P140 remains a core value driver for ImmuPharma. The Company continues to progress discussions with a number of potential partners, including under signed confidentiality agreements. The management team also attended the Bio-Europe Spring healthcare event in Lisbon this week, where a number of meetings were held in relation to P140. ImmuPharma remains focused on completing a value-enhancing licensing deal in 2026. ImmuPharma will provide further updates on the P140 program as appropriate.
お知らせ • Mar 23ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £0.468747 million.ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £0.468747 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,812,447 Price\Range: £0.06
お知らせ • Mar 17ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £6 million.ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 100,000,000 Price\Range: £0.06
New Risk • Feb 22New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (UK£42.7m market cap, or US$57.6m).
お知らせ • Oct 13ImmuPharma plc Announces Appointment of Ketan Patel as an Independent Non-Executive Director, effective October 13, 2025ImmuPharma plc announced the appointment of Ketan Patel to the Board, as an independent Non-Executive Director. The appointment is with immediate effect October 13, 2025. Ketanis an experienced investment professionaland brings extensive expertise in financial markets with a focus in the UK healthcare and life science sectors. He has been a long-term investor in UK markets, as an analyst and Fund Manager, running institutional, retail and charity mandates. Ketan started his career at JP Morgan, before moving to Insight Investment where he was a global Pharmaceutical and Healthcare analyst and spent over 20 years at EdenTree Investment Management where he was responsible for UK equity and global equity income strategiesdelivering consistent upper quartile performance. Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes, Ketan is a CFA Charterholder. He also holds anMSc Economic History, fromLondon School of Economics, MSc Geography from King's College London and BA (Hons) History and Geography from Queen Mary University, London.
Board Change • Sep 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Senior Independent Non-Executive Director Laurence Reilly was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Aug 06New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£1.9m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (UK£8.43m market cap, or US$11.3m).
お知らせ • May 20ImmuPharma plc, Annual General Meeting, Jun 12, 2025ImmuPharma plc, Annual General Meeting, Jun 12, 2025. Location: the malmaison hotel, 18 21 charterhouse square, barbican, ec1m 6ah, london United Kingdom
New Risk • May 19New major risk - Negative shareholders equityThe company has negative equity. Total equity: -UK£543k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Negative equity (-UK£543k). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (UK£15.0m market cap, or US$20.0m).
New Risk • Apr 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (UK£18.5m market cap, or US$24.6m).
New Risk • Mar 28New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (58% average weekly change). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (UK£12.7m market cap, or US$16.5m).
お知らせ • Feb 21ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £2.9095 million.ImmuPharma plc has completed a Follow-on Equity Offering in the amount of £2.9095 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,586,667 Price\Range: £0.0375 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: £0.0375 Transaction Features: Subsequent Direct Listing
お知らせ • Feb 14ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £2.9095 million.ImmuPharma plc has filed a Follow-on Equity Offering in the amount of £2.9095 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 27,586,667 Price\Range: £0.0375 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 50,000,000 Price\Range: £0.0375 Transaction Features: Subsequent Direct Listing
分析記事 • Jan 25Is ImmuPharma (LON:IMM) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
お知らせ • Jan 09ImmuPharma plc Announces Breakthrough Findings into Autoimmune DiseasesImmuPharma PLC announced innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company's R&D subsidiary ImmuPharma Biotech, has yielded data that provides novel insights into autoimmune disease mechanisms. Importantly for autoimmune therapy P140, especially for lead indication in SLE, these findings pave the way for: Earlier and more accurate diagnostics; Identifying patients most likely to respond to P140 therapy; and Improved monitoring of the patient's response to treatment with P140. Through this research, the company is making a significant step towards personalised medicine in SLE and other autoimmune diseases. The Company is not at this time releasing detailed data as these findings form part of the ongoing expansion of intellectual property portfolio including additional patents for P140.
New Risk • Jan 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.6m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£5.23m market cap, or US$6.53m).
お知らせ • Dec 04Immupharma plc Announces Appointment of Ashley Clarke as Company SecretaryImmuPharma plc to confirm the appointment of Ashley Clarke ACA, as Company Secretary to the Company. The appointment is with immediate effect. Ashley has been closely involved with the Company's accounts for several years via outsourced accountants, providing her with deep familiarity with ImmuPharma's operations. Now, as Group CFO, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure continued robust fiscal management. (More details on Ashley in 'Notes to Editors').
お知らせ • Sep 17Immunovia Presents Data from Model Development Study At 2024 AACR Advances in Pancreatic Cancer Medical ConferenceImmunovia presented detailed model-development study results at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer. Immunovia shared results from the model development study of its next-generation test to detect stage 1 and 2 pancreatic cancer. The company disclosed its method for selecting the biomarkers that comprise the test, the construction of the test algorithm, and the test's performance and stability. In the study of 623 patient samples, the test demonstrated superior performance, with sensitivity of 85% and specificity of 98%, as reported in a 1 August 2024 press release. The sensitivity of the Immunovia test exceeded that of CA19-9, a commonly used biomarker for pancreatic cancer, by 20 percentage points. The conference is being hosted by the American Association for Cancer Research (AACR) in Boston, Massachusetts. This special conference brings together leading pancreatic cancer researchers, physicians, and patient advocates to share innovative approaches for diagnosing and treating pancreatic cancer.
お知らせ • Jul 29ImmuPharma plc to Report Q2, 2024 Results on Aug 05, 2024ImmuPharma plc announced that they will report Q2, 2024 results at 8:30 AM, Central European Standard Time on Aug 05, 2024
お知らせ • Jun 08ImmuPharma plc, Annual General Meeting, Jun 28, 2024ImmuPharma plc, Annual General Meeting, Jun 28, 2024. Location: the offices of evelyn partners, 45 gresham street, ec2v 7bg, london United Kingdom
お知らせ • Apr 30Immunovia Announces the Appointment of Lisa Fordas as Clinical Laboratory DirectorImmunovia announced the appointment of Dr. Lisa Fordas Clinical Laboratory Director. As Clinical Laboratory Director, Dr. Ford will lead lab operations as well as research and development of Immunovia's next-generation test. Her primary responsibilities will be staffing, developing, and overseeing the laboratory team; quality assurance and regulatory compliance; and facilitating collaboration and communication with external partners, especially Proteomedix. Lisa brings over twenty years of experience leading laboratory project teams through research, development, validation (clinical and analytical) and implementation of diagnostic tests. She has extensive experience overseeing clinical and bioanalytical laboratories and associated quality systems, managing clinical assay development, validation projects, quality improvement and laboratory personnel. Lisa holds a Ph.D. from Duke University in Bioorganic Chemistry and a B.S. from University of California in Chemistry, and board certification as a high-complexity clinical laboratory director from the American Board of Bioanalysis.
New Risk • Mar 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.5m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (UK£70k revenue, or US$89k). Market cap is less than US$10m (UK£7.72m market cap, or US$9.84m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (25% increase in shares outstanding).
お知らせ • Dec 19Immupharma plc Announces Key Updates on Its Late Stage P140 Program, in Patients with Systemic LupuzortmImmuPharma PLC announced key updates on its late stage P140 (Lupuzortm) program, in patients with systemic lupus erythematosus ("SLE/Lupus"). The design of the pivotal Phase 3 study includes a dose-range. This design is faster to complete than a Phase 2/3 adaptive study, while at the same time incorporating all the key objectives. The company confidently expect the efficacious dose to be within this dose-range and The company expects no adverse events that could lead to product label warnings seen with all other approved drugs and standard of care, which are all immunosuppressants. The study design allows two interim analyses, so there will be short term updates on clinical activity of the drug. P140 is not an immunosuppressant, so a key objective will be to taper the use of steroids which are currently standard of care. This distinction sets the stage for a new gold standard therapy, conveniently self-administered by the patient, once a month, which is safe and well tolerated unlike standard of care or any other molecule in development which are all immunosuppressedants with significant safety warnings. Further details on the protocol and key elements of the clinical trial design will be communicated, once the details of the trial are available on clinicaltrials.gov (a comprehensive database of privately and publicly funded clinical studies conducted around the world). The international Phase 3 dose-ranging study design and protocol is substantially different from previous clinical trials completed by ImmuPharma. Dosing will still be a subcutaneous injection, once a month, but with significantly higher doses, which have demonstrated safety and tolerability as part of the clinical program. Two planned interim analyses during the course of the study will allow early indications of the effectiveness of P140. Recent further insights into P140's mechanism of action supports its position as the only non-immunosuppressing molecule in clinical development in the industry. A new potential standard of care for SLE sufferers. As the study continues to move forward in 2024, further details on the study's timings, protocol and key elements of theclinical trial design will be communicated at regular intervals. Simbec-Orion, is an experienced, full-service Contract Research Organisation, with offices across UK, Europe, and the United States, specialising in Rare & Orphan conditions. Simbec-Orion has previous direct experience in Lupus trials including conducting ImmuPharma's last Phase 3 study completed in 2018 and more recently conducted ImmuPharma's Pharmacokinetics (" PK") study completed in 2022. The whole P140 program was re-examined in 2021, and the Board decided that it required a completely different approach, not only to commence a new Phase 3 study in Lupus, but also to be clear on the product offering and target product profile. The three pillars of strength and confidence in new program are dose, design and MOA. Dose After three FDA guidance meetings, further human and animal pharmacokinetics studies and reconciliation with efficacy demonstrated in the animal models, it was concluded that the previous dose used in clinical studies was too low. The new Phase 3 study will include dose-ranging up to 15 times higher than the original study dose of 200 micrograms. Design The design of the pivotal Phase3 study includes a dose- range. This design is faster to completed than a Phase 2/3 Adapted study, while at the sametime incorporating all the key objectives.
お知らせ • Nov 09Immunovia Successfully Completes Discovery Phase of Next-Generation Test DevelopmentImmunovia announced the successful completion of the discovery phase for the Company's next-generation test. The discovery study, which marks a key milestone in the development of Immunovia's next-generation test to detect early-stage pancreatic cancer, successfully found more than a dozen proteins circulating in the blood that identified pancreatic ductal adenocarcinoma (PDAC) stage I and stage II patients. The study is the most comprehensive pancreatic proteomics study done to date and utilized the Olink platform to explore nearly 3,000 protein biomarkers. The new test is designed to work across all racial and ethnic groups without compromising accuracy, overcoming a key limitation of Immunovia's first-generation test, IMMray PanCan-d. Immunovia and its development partner Proteomedix are in the process of developing high- quality assays to accurately measure the identified biomarkers. The next step will be to complete a study to select which biomarkers to include in the commercial test, optimize the test, and assess its accuracy. Later in 2024, Immunovia will confirm the analytical validity of the test and conduct a large clinical validation study.
Board Change • Oct 12No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 4 new directors. No experienced directors. 6 highly experienced directors. No independent directors (5 non-independent directors). Member of Scientific Advisory Board Cees Kallenberg is the most experienced director on the board, commencing their role in 2013. Senior independent Non-Executive Director Laurence Reilly was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Aug 12ImmuPharma plc Announces Changes to Its Board of DirectorsImmuPharma plc announced the appointment of Dr. Laurence Reilly as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr. Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience. He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry. Through his consulting practice (Acumen Life Science Investment Consulting) .Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr. Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr Reilly previously served as a Clinician - Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor. Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K. The company also extremely welcomed DrSébastien Goudreau to the Board. Dr Goudreau joined ImmuPharma in 2014 as research director and established the research laboratories of Ureka Pharma (now ImmuPharma Biotech, the Company's French subsidiary) in Bordeaux, being promoted in 2021 to Chief Executive Officer of ImmuPharma Biotech. Notably, working directly with Dr Tim Franklin (ImmuPharma COO), Dr Goudreau and his team are credited for the development of, among others, the Company's anti-infective programmes, BioAMBand BioCin. Dr Goudreau has also been a key contributor to the progression of the P140 autoimmune platform including the PK study, successfully concluded in 2022, and supported the new protocol design of the Phase 2/3 adaptive clinical studies for both Lupus and CIDP. Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. At this time, Dr Sanjeev Pandya, has informed the Board that he wishes to step down from his Non-Executive Director position, in order to pursue a number of other external opportunities. All Board changes take place with immediate effect.
お知らせ • Jul 13Immunovia to Significantly Restructure to Focus Resources on Its Next-Generation Blood Test for Pancreatic Cancer DetectionImmunovia announced plans to restructure its operations. The company will cease commercialization of its IMMray PanCan-d test in the United States to focus its resources on the further development and clinical testing of the Company's promising next generation pancreatic cancer detection test. The next generation assay currently in development is intended to work equally well across multiple patient risk groups. The new test is expected to provide accurate results in patients who do not produce CA19-9, and to reduce reliance on CA19-9, which have been limitations of IMMray PanCan-d. The next generation test will be performed on a widely used commercial platform, enabling the company to better scale production. Immunovia expects to release further details about the next-generation test later this year, with an anticipated launch date in 2024. Immunovia's strategic decision to focus on its next generation assay will result in significant layoffs in both Sweden and the United States in multiple functions. Importantly, the staffing reductions and the elimination of other operating expenses will lower the company's cash burn rate and extend the Company's cash reserves well into 2024.
New Risk • Jun 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: UK£7.82m (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£2.5m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (UK£7.82m market cap, or US$9.94m). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding).
お知らせ • Jun 06ImmuPharma plc, Annual General Meeting, Jun 30, 2023ImmuPharma plc, Annual General Meeting, Jun 30, 2023, at 10:00 Coordinated Universal Time. Location: One Bartholomew Close London, EC1A 7BL London United Kingdom
お知らせ • May 23ImmuPharma plc, Annual General Meeting, May 26, 2023ImmuPharma plc, Annual General Meeting, May 26, 2023, at 09:00 Central European Standard Time. Location: The Spark, Scheeletorget 1, Medicon Village, Lund. Lund Sweden
お知らせ • May 19+ 1 more updateImmuPharma plc Announces Further Positive Progress in Late-Stage Clinical Program in Patients with Chronic Idiopathic Demyelinating PolyneuropathyImmuPharma PLC announced further positive progress in its late-stage clinical program in patients with chronic idiopathic demyelinating polyneuropathy, which is a further debilitating auto-immune condition within the Company's P140 platform. Key highlights: ImmuPharma has received positive support and guidance from the Food and Drug Administration ("FDA"), following the Pre-Investigational New Drug ("PIND") meeting that confirms the route for a Phase 2/3 adaptive clinical study of P140 in CIDP; The FDA feedback recognises that P140 is suitable to be studied in another disease indication in addition to SLE (systemic lupus erythematosus) and this strongly supports the underlying science and mechanism of action of P140 across several auto-immune/inflammatory diseases and is a significant breakthrough for the P140 platform; The Phase 2/3 adaptive clinical trial will be the first pivotal stage study of P140 in patients with CIDP: a rare neurological disease with high medical need; An IND application will now be prepared for submission to the FDA, incorporating all guidance points and pending approval, company remain on track to commence the Phase 2/3 adaptive clinical trial in H2 2023; An application for Orphan Drug status for CIDP will be also submitted in parallel to the full IND application; The CIDP market is expected to reach global sales of USD 2.7 billion by 2029. This feedback from the FDA provides not only positive support and guidance for an IND application and acceptance of the Phase 2/3 clinical trial design for CIDP, but also recognises the potential therapeutic benefit in another auto-immune/inflammatory disease in addition to P140 (Lupuzor™) in SLE, representing a significant breakthrough for the P140 platform. The Phase 2/3 clinical trial will be the first pivotal stage study of P140 in patients with CIDP: a rare neurological disease with high medical need. The study design was developed with company's contract research organisation (CRO) and CIDP opinion leaders from Europe and the USA. The CIDP protocol is founded on much of the preclinical and clinical work carried out to date on P140 (Lupuzor™) in SLE, which itself is scheduled to begin a Phase 2/3 adaptive clinical trial in Lupus patients in H2 2023. Many elements of the FDA guidance for CIDP, particularly the Phase 2/3 protocol design and dosing, can now be anticipated for the upcoming FDA Type-C meeting for P140 (Lupuzor™) in SLE on or around the 7th June 2023.
お知らせ • Jan 20Immunovia Announces Realigning Swedish Operations with Strategic Priorities and Its Focus on the US Commercialization of the IMMray™ PanCan-d testImmunovia announced it is realigning its Swedish operations with its strategic priorities to drive R&D productivity and focus on the US commercialization of the IMMray™ PanCan-d test. In October 2022, Immunovia announced a research collaboration partnership with Proteomedix. The partnership capitalizes on the combined expertise of two leading innovators in proteomics-based diagnostics. Following the early experience of the collaboration Immunovia has been able to better understand the opportunities available to the company and has determined that the in-house need for R&D capability has changed. As a result, Immunovia has initiated a union consultation process with the aim of reducing the number of employees within R&D and Operations in Lund. Immunovia has initiated a consultation process with relevant Swedish unions to create the best possible transition for the affected employees. The Company will provide an update once the consultation process is concluded.
お知らせ • Jan 18Immunovia Appoints Lara E. Sucheston-Campbell as Head of Clinical and Medical Affairs to Accelerate Commercial strategy of IMMray PanCan-d test in the US marketImmunovia announced that it has appointed Lara E. Sucheston-Campbell as the Head of Clinical and Medical Affairs effective February 1, 2023. Lara joins Immunovia from Roche Molecular Systems, where she served as Global Director of Clinical Development in Oncology and Genetics. Prior to joining Roche, she spent over 13 years in academia, most recently as a tenured Associate Professor at The Ohio State University. Her lab focused on the contribution of genomics to cancer susceptibility and survival following diagnosis. Lara brings expertise in designing, implementing, analyzing, and leading large-scale international clinical, biomarker, genomic and epidemiologic studies resulting in national and international scientific presentations and over 130 peer-reviewed publications. Her academic research was funded by the National Institutes of Health and Department of Defense. She has extensive experience in leading clinical science teams and collaborating with key opinion leaders. Lara holds a PhD in Genetic and Molecular Epidemiology from Case Western Reserve University, an MS in Genetic Counseling from The Ohio State University as well as degrees in engineering and economics.
Price Target Changed • Nov 16Price target decreased to UK£0.029Down from UK£0.036, the current price target is provided by 1 analyst. New target price is 16% above last closing price of UK£0.025. Stock is down 63% over the past year. The company posted a net loss per share of UK£0.033 last year.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Senior Independent Non-Executive Director Sanjeev Pandya was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 12+ 4 more updatesImmuPharma plc, Annual General Meeting, Apr 27, 2023ImmuPharma plc, Annual General Meeting, Apr 27, 2023.
Reported Earnings • Sep 30First half 2022 earnings released: UK£0.006 loss per share (vs UK£0.015 loss in 1H 2021)First half 2022 results: UK£0.006 loss per share (improved from UK£0.015 loss in 1H 2021). Net loss: UK£1.66m (loss narrowed 55% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
Reported Earnings • May 26Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: UK£0.032 loss per share. Net loss: UK£8.17m (loss widened 19% from FY 2020). Revenue exceeded analyst estimates by 18%. Earnings per share (EPS) missed analyst estimates by 12%.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Senior independent Non-Executive Director Sanjeev Pandya was the last independent director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 03First half 2021 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in 1H 2020)First half 2021 results: Net loss: UK£3.66m (loss widened 24% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Board Change • Aug 10Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Senior independent Non-Executive Director Sanjeev Pandya was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Executive Departure • Aug 05Independent Non-Executive Director Stéphane Robert Méry has left the companyOn the 30th of July, Stéphane Robert Méry's tenure as Independent Non-Executive Director ended after 6.3 years in the role. As of March 2021, Stéphane Robert still personally held only 21.49k shares (UK£1.9k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Aug 05Senior Independent Non-Executive Director Franco Di Muzio has left the companyOn the 30th of July, Franco Di Muzio's tenure as Senior Independent Non-Executive Director ended. As of March 2021, Franco still personally held only 99.41k shares (UK£8.8k worth at the time). A total of 3 executives have left over the last 12 months. The current median tenure of the management team is 1.25 years, which is considered inexperienced in the Simply Wall St Risk Model.
Executive Departure • Jul 02Co-Founder, President, Chief Scientific Officer & Director D. Henri Zimmer has left the companyOn the 28th of June, D. Henri Zimmer's tenure as Co-Founder, President, Chief Scientific Officer & Director ended after 15.4 years in the role. As of March 2021, Henri Zimmer still personally held 27.34m shares (UK£2.4m worth at the time). Henri Zimmer is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.33 years, which is considered inexperienced in the Simply Wall St Risk Model.
分析記事 • Jun 22Shareholders May Be A Bit More Conservative With ImmuPharma plc's (LON:IMM) CEO Compensation For NowThe underwhelming share price performance of ImmuPharma plc ( LON:IMM ) in the past three years would have disappointed...
Reported Earnings • May 01Full year 2020 earnings released: UK£0.034 loss per share (vs UK£0.04 loss in FY 2019)Full year 2020 results: Net loss: UK£6.86m (loss widened 12% from FY 2019). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings.
分析記事 • Dec 02How Much Is ImmuPharma's (LON:IMM) CEO Getting Paid?The CEO of ImmuPharma plc ( LON:IMM ) is Dimitri Dimitriou, and this article examines the executive's compensation...
Reported Earnings • Oct 03First half earnings releasedOver the last 12 months the company has reported total losses of UK£5.18m, with losses narrowing by 26% from the prior year.
